SLC5A2 and chronic kidney disease: For example, the use of renoprotective interventions, such as renin angiotensin aldosterone system inhibitors36 and inhibitors of sodium-glucose cotransporter 2, might provide a potential means to do so.37 Our findings encourage additional evaluation of such agents in patients with CKD without manifest CVD or diabetes.38,39